Bile duct cancer
A two-arm randomized phase III, open-label prospective non-inferiority study ofirinotecan versus oxaliplatin or 5-FU based chemotherapy mFOLFOX or CAPOX forpatients with locally advanced/ metastatic biliary tract cancers BTC previouslytreated with gemcitabine-cisplatin based chemotherapy.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Registry summary (technical)
A two-arm randomized phase III, open-label prospective non-inferiority study of irinotecan versus oxaliplatin / 5-FU based chemotherapy (mFOLFOX/CAPOX) for patients with locally advanced/ metastatic biliary tract cancers (BTC) previously treated with gemcitabine-cisplatin based chemotherapy. - (BTC-SELECT)
Sponsor: Tata Memorial Hospital
CTRI/2022/01/039568 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 1 Jun 2026 · read by us 5 Nov 2026